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Edited by Hans-Dieter KlenkAbstract The non-nucleoside reverse transcriptase inhibitor,
efavirenz (EFV), is a potent enhancer of human immunodeﬁ-
ciency virus type 1 (HIV-1) reverse transcriptase (RT) p66/p51
heterodimerization. While the mechanism of RT heterodimer
formation in HIV-1 infected cells is not completely understood,
it has been speculated that Gag–Pol/Gag–Pol and/or RT
homodimer interactions may represent important intermediates
in the pathway. To elucidate whether EFV impacts on these
interactions, we have evaluated the eﬀects of this drug on RT
homodimer interactions and HIV-1 Gag–Pol processing. EFV,
but not nevirapine, signiﬁcantly enhanced RT p66/p66 and p51/
p51 homodimer interactions and accelerated the proteolytic
cleavage of a model HIV-1 Pol polyprotein precursor expressed
in bacteria. These data suggest that potent mediators of
RT dimerization might interfere with the late-stages of viral
replication.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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NNRTI1. Introduction
The human immunodeﬁciency virus type 1 (HIV-1) reverse
transcriptase (RT) exhibits both DNA polymerase and ribonu-
clease H (RNase H) activities and catalyzes the conversion of
the viral RNA genome into a double-stranded proviral DNA
precursor. The biologically relevant form of HIV-1 RT is a
heterodimer composed of 66 (p66) and 51 kDa (p51) polypep-
tides. The p51 subunit is derived from, and is identical to, theAbbreviations: HIV-1, human immunodeﬁciency virus type 1; RT,
reverse transcriptase; NNRTI, non-nucleoside reverse transcriptase
inhibitor; EFV, efavirenz; PR, protease; NC, nucleocapsid; TFR,
trans-frame region; IN, integrase; Y2H, yeast-two hybrid; SEC, size-
exclusion chromatography; GST, glutathione S-transferase
*Corresponding author. Fax: +61 3 9282 2100.
E-mail address: gildat@burnet.edu.au (G. Tachedjian).
0014-5793/$22.00  2004 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2004.11.099N-terminal polymerase domain of p66 [1]. The p66/p51 HIV-1
RT heterodimer contains one functional DNA polymerase ac-
tive site and one functional RNase H active site, that both re-
side in the p66 subunit of the enzyme which adopts an ‘‘open’’
structure to accommodate the nucleic acid template/primer
[2,3]. In contrast, p51 assumes a ‘‘closed’’ conformation and
plays largely a structural role in the p66/p51 heterodimer [4–6].
The p66 and p51 subunits of HIV-1 RT are not synthesized
de novo, but are initially translated as part of a larger 160 kDa
polyprotein termed Gag–Pol consisting of the Gag-encoded
structural proteins matrix, capsid, p2 and nucleocapsid (NC),
and the Pol-encoded functional enzymes protease (PR), RT
and integrase (IN). A trans-frame region (TFR) links the
Gag and the Pol domains and consists of an N-terminal octa-
peptide and p6pol that are separated by a cleavage site [7]. A
PR cleavage site separates each of the distinct protein domains
in Gag–Pol and Pol-encoded PR is responsible for cleavage of
the polyprotein [8] during or shortly after viral particle release
[9]. The pathways involved in PR activation, subsequent cleav-
age of the Gag–Pol polyprotein and p66/p51 RT dimer forma-
tion, have not been well deﬁned. However, previous studies
have suggested that one of the early cleavage events involved
in the auto-processing of PR occurs within the TFR which
leads to the accumulation of a 114 kDa polyprotein intermedi-
ate comprising the p6pol, PR, RT and IN [10–13]. PR auto-
processing from the Pol polyprotein involves intra-molecular
cleavage of the TFR–PR junction [14] and intermolecular
cleavage of the PR–RT junction [15]. Based on a model 90
kDa Pol polyprotein (which comprises the TFR, PR, RT
and the N-terminus of IN), the kinetics of RT processing fol-
lows an ordered sequential pathway in which RT p66 is ﬁrst
excised from the Pol polyprotein, followed by formation of
the p51 subunit. Processing of the p66 subunit to p51 appears
to proceed through a p66/p66 RT homodimer precursor as
mutations known to abrogate HIV-1 RT dimerization prevent
cleavage of p66 to p51 in this model system [16].
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
comprise a group of small amphiphilic compounds [17–19] that
inhibit HIV-1 RT by binding to a hydrophobic pocket that is
proximal to the polymerase active site [20,21]. Previous studies
have shown that the NNRTI efavirenz (EFV) is a potent en-
hancer of HIV-1 RT heterodimerization, with this eﬀect beingblished by Elsevier B.V. All rights reserved.
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pocket in the p66 subunit of the enzyme [22]. While the eﬀect
of EFV on RT heterodimerization is known [19,22], the impact
of this drug on p66 and p51 homodimerization has not been
demonstrated. Furthermore, it is not known if this drug would
impact on Gag–Pol processing and potentially inﬂuence the
late-stages of viral replication. This study was carried out to
address these questions.2. Materials and methods
2.1. Reagents
EFV and nevirapine were obtained from the AIDS Research and
Reference Reagent Program, NIAID, NIH. Delaviridine was pur-
chased from Biomol (Plymouth Meeting, PA). The monoclonal anti-
bodies mAb 5B2 and mAb 6G5 were generously provided by Dag
Helland and recognize both HIV-1 RT subunits [23] and the N-termi-
nal 16 amino acids of the HIV-1 IN, respectively [24].
2.2. Bacterial and yeast strains and expression constructs
Saccharomyces cerevisiae strain CTY10-5d (MATa ade2 trp1-901
leu2-3,112, his3-200 gal4gal80 URA3::lexA-lacZ) contains an inte-
grated GAL1-LacZ gene with the lexA operator (a gift from Stanley
Fields, State University of New York, Stony Brook). The ‘‘bait’’ con-
structs p66SH2-1 and p51SH2-1 express the p66 and p51 RT subunits
fused to the N-terminal lexA DNA binding domain in yeast [25]. The
‘‘prey’’ constructs p66GADNOT and p51GADNOT express the p66
and p51 RT subunits fused to the N-terminal Gal4 activation domain
(Gal4 AD) in yeast and were cloned as previously described [25].
Escherichia coli strain M15 (Qiagen) was used to express p66 with a
C-terminal histidine tag (p66-His) from plasmid pQE70 [25], p51 with
a N-terminal histidine tag (His-p51) from plasmid p6HRT51 [26] and
p66 with a N-terminal histidine tag (His-p66) from plasmid p6HRT
[27]. The p66 (GST-p66) and p51 (GST-p51) RT subunits fused to
N-terminal glutathione S-transferase (GST) were expressed in E. coli
strain BL21 [25]. The model Pol was expressed by transfection of
BL21(DE3)LysS with the vector, pol-pET28a(+) [16].
2.3. Yeast-two hybrid (Y2H) assay for RT dimerization
Transformation of yeast with the ‘‘bait’’ and ‘‘prey’’ constructs was
performed as published [28]. Quantiﬁcation of protein:protein interac-
tions was determined using the b-galactosidase (b-gal) liquid assay
performed on permeabilized yeast grown from three independent trans-
formants using ortho-nitrophenyl-b-D-galactopyranoside (ONPG) as
published [29].
2.4. Protein expression in yeast
To prepare yeast protein extracts for Western blot analysis, yeast
transformants were grown as described for the b-gal liquid assay
[29], except that the cells were diluted into a total volume of 8 ml.
Growth conditions and extraction of protein are as published in [29].
Fusion protein expression in yeast was determined by Western blot
analysis of lysates with Gal4AD polyclonal antibodies (Upstate Bio-
technology, Lake Placid, NY) and anti-lexA polyclonal antibodies
(Invitrogen, Carlsbad, CA). Immunodetection was with ECL-Plus
(Amersham Biosciences, Sydney, NSW).2.5. In vitro binding assays
In vitro binding assays to analyze p66 and p51 homodimerization
were performed as described previously [29]. For p66 homodimeriza-
tion, GST-p66 (0.04 lM) and p66-His (0.09 lM) were incubated in
the absence or presence of 3–300 molar excess of EFV (relative to
GST-p66) for 16 h at 4 C. For analysis of p51 homodimerization,
GST-p51 (0.3 lM) and His-p51 (0.4 lM) were incubated in the absence
and presence of 0.4–40 molar excess of EFV (relative to GST-p51) as
above. Dimers were captured using Ni-NTA agarose aﬃnity chroma-
tography. Following the binding of p66-His or His-p51 to the Ni-NTA
agarose, samples were washed extensively, resolved by SDS–PAGE
and subjected to Western blot analysis using mAb 5B2.2.6. Size-exclusion chromatography
Recombinants His-p66 [27] and His-p51 [26] were puriﬁed by Ni-
NTA and DEAE-Sepharose chromatography as previously described
[30]. Separation of RT monomers and homodimers was performed
by size-exclusion chromatography (SEC) using a Superdex 200 column
(Amersham Biosciences) and FPLC. Elution of RT subunits was com-
pared to the elution proﬁles of a mixture of eight molecular weight
standards for gel ﬁltration (range 669–13.7 kDa) as per the manufac-
turers instructions (Amersham Biosciences). Samples (200 ll) were re-
solved in running buﬀer (50 mM sodium phosphate, pH 7.8 and 150
mM NaCl) at a ﬂow rate of 0.25 ml/min. To examine the eﬀect of
EFV on RT homodimerization, puriﬁed His-p66 and His-p51 were di-
luted in running buﬀer to a ﬁnal concentration of 3.8 and 4.9 lM,
respectively, and resolved by SEC after 0, 2 and 16 h incubation on
ice in the presence of 0-, 1- and 10-fold molar excess of EFV relative
to total protein.2.7. Processing of model Pol polyprotein
The cloning and overexpression of the 90 kDa HIV-1 Pol polypro-
tein have previously been described. Brieﬂy, E. coli transformed with
pol-pET28a(+) were cultured overnight and diluted 100-fold in fresh
culture medium in the absence and presence of 5 lM EFV, nevirapine
or delavirdine at 37 C. Protein expression was induced by the addition
of 1 mM isopropyl-b-D-thiogalactoside (IPTG) when cells reached 0.6
A600. At speciﬁed times post-induction, cell equivalents to 0.2 A600 unit
were pelleted and processed as previously described [16]. Samples were
resolved by SDS–PAGE on a 4–15% gradient gel and subjected to
Western blot using RT (mAb 5B2) and IN (mAb 6G5) antibodies.3. Results
3.1. Impact of EFV on p66 and p51 homodimerization in the
Y2H system
To assess the eﬀect that EFV has on p66/p51, p66/p66 and
p51/p51 HIV-1 RT dimerization, yeast co-transformed with
the appropriate ‘‘bait’’ and ‘‘prey’’ expression vectors were
propagated in the absence and presence of increasing concen-
trations of EFV. Equivalent cell numbers were then subjected
to b-gal liquid assays. The b-gal activities for p66/p51, p66/p66
and p51/p51 RT dimerization in the absence of drug were 1.2,
0.06 and 0.04 Miller units, respectively, consistent with previ-
ous reports on the relative stabilities of these dimers [31–33].
EFV conferred a dose-dependent increase (20-fold) in b-gal
activity for RT heterodimerization (Fig. 1A; [22]). Interest-
ingly, EFV dramatically increased the b-gal activity in yeast
expressing p66 bait and p66 prey fusions with a 100-fold in-
crease at P 1 lM of drug compared to untreated cells (Fig.
1A). In contrast, EFV conferred only a modest (4-fold) in-
crease in b-gal activity in yeast expressing p51 ‘‘bait’’ and
p51 ‘‘prey’’ fusions at 5 lM EFV (Fig. 1A). Our previous stud-
ies demonstrate that EFV can also enhance RT heterodimer-
ization of dimerization defective RT mutants [22].
Examination of the impact of EFV on enhancing p66 homod-
imerization in yeast expressing p66 ‘‘bait’’ with the L234A
mutation and wild-type p51 ‘‘prey’’ demonstrated that EFV
can also enhance homodimerization of dimerization defective
RT mutants (results not shown).
To exclude the possibility that the observed increase in b-gal
activity in the p66 homodimer assay was due to RT heterodi-
merization resulting from the proteolysis of p66 bait and/or
prey fusions to p51, Western blot analyses of the yeast lysates
were performed (Fig. 1B). We were unable to detect bands cor-
responding to p51 ‘‘bait’’ or ‘‘prey’’ in these lysates suggesting
that we were detecting speciﬁc RT homodimer interactions in
the Y2H system.
Fig. 1. Y2H b-gal liquid assay demonstrating the enhancement by
EFV of p66/p51, p66/p66 and p51/p51 dimerization. The data are the
average of three independent assays and the b-gal activity is expressed
as Miller units. Yeast strain CTY10-5d expressing lexA87-66 and
Gal4AD-51 (p66/p51), lexA87-66 and Gal4AD-66 (p66/p66), and
lexA87-51 and Gal4AD-51 (p51/p51) (A). Western blot analysis of
yeast expressing p66 and p51 bait and prey fusion proteins grown in
the absence or presence of 5 lM EFV. Expression of bait and prey
fusions was detected with anti-lexA and anti-Gal4 AD antibodies,
respectively (B).
Fig. 2. Western blot analysis of p66 and p51 homodimers formed in
the presence of EFV in an in vitro binding assay. GST-p66 and p66-
His incubated in the absence (0) and presence of EFV (A). GST-p51
and His-p51 incubated in the absence (0) and presence of EFV (B). W,
denotes incubations performed in the absence of p66-His (A) or His-
p51 (B).
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and SEC
To conﬁrm the Y2H data, we performed in vitro binding
assays using recombinant p66 and p51 fusion proteins. Incuba-
tion of GST-p66 and p66-His with EFV resulted in a dose-
dependent increase in co-precipitated GST-p66 indicating that
EFV enhanced p66 homodimerization in vitro (Fig. 2A). A
band most likely representing a bacterial proteolytic degrada-
tion product of GST-p66 to GST-p51 was observed at 30 and
300 molar excess of EFV, suggesting that RT heterodimeriza-
tion was competing with p66 homodimerization in this system.
Similar experiments with GST-p51 and His-p51 demonstrated
that EFV also enhanced p51 homodimerization (Fig. 2B).
We also investigated RT homodimer interactions using SEC.
Puriﬁed recombinants His-p66 [27] and His-p51 [26] were incu-
bated with 1- or 10-fold molar excess of drug compared to to-
tal protein. In the absence of EFV, two protein peaks were
resolved that correlated with molecular weights consistent with
p66 or p51 homodimer (132 or 102 kDa, respectively) and
monomer (66 or 51 kDa, respectively) (Fig. 3A and B). In con-
trast to the p66 homodimer, the p51 homodimer was unstableand essentially reverted to monomer after overnight incuba-
tion. This result is consistent with the notion that p51 homodi-
mer is thermodynamically unfavorable [31]. However, in the
presence of a 1- or 10-fold molar excess of EFV, the equilib-
rium for both p66 and p51 was pushed toward dimer forma-
tion (Fig. 3A and B). The presence of a signiﬁcant amount
of p51/p51 homodimer at 0 h incubation in the absence of drug
appears to be surprising given that the dissociation constant
for p51 is 105 M [25]. However, this observation can be ex-
plained by the fact that p51 was diluted from a concentrated
stock (146 lM) and did not have suﬃcient time to reach equi-
librium at the ﬁnal concentration of 4.9 lM.
3.3. Eﬀect of EFV on processing of a model Pol polyprotein
Since p66 is expressed as part of the Gag–Pol polyprotein we
wanted to determine whether EFV could bind to RT in the con-
text of larger polyprotein and possibly inﬂuence PR activation,
polyprotein processing and p66/p51 RT dimer formation. To
investigate this we used a model 90 kDa HIV-1 Pol polyprotein
construct which expresses the last four amino acids of NC,
TFR, PR, RT and the ﬁrst 44 amino acids of IN in an inducible
bacterial expression system [16]. Cells were grown in the
absence or presence of EFV and sampled at various times post-
induction (Fig. 4). In the absence of drug, we observed the ini-
tial appearance of the 90 kDa Pol polyprotein, which was
sequentially cleaved to p66 and some p51. However, in the pres-
ence of EFV the rate of processing of the 90 kDa protein to p66
and subsequently to p51 was signiﬁcantly enhanced. Further-
more, the ratio of p66 to p51 was closer to 1:1 at equivalent
times post-induction than in the absence of drug. Similar
Fig. 3. Separation of RT monomers and homodimers incubated in the absence and presence of EFV by SEC. His-p66 incubated in the absence or
presence of 0-, 1- and 10-fold molar excess of EFV relative to His-p66 (A). His-p51 incubated in the absence or presence of 0-, 1- and 10-fold molar
excess of EFV relative to His-p51 (B).
Fig. 4. Western blot analysis of sequential processing products from a model Pol construct, pol-pET28a(+), expressed in E. coli strain
BL21(DE3)pLysS and grown in the absence or presence of 5 lMEFV. Blots were probed with mAb 5B2 (anti-RT) and mAb 6G5 (anti-IN). PI (min),
time post-induction in minutes.
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lack RT dimerization enhancing activities (delavirdine) [22]
resulted in a processing pattern similar to wild-type (Fig. 4).
These data demonstrate that EFV binds to and alters the pro-
cessing of a model Pol polyprotein expressed in bacteria.4. Discussion
Previous studies have demonstrated that EFV signiﬁcantly
enhances the subunit–subunit interactions in p66/p51 HIV-1
RT [19,22]. However, the biological signiﬁcance of this ﬁndingis unknown. The p66 and p51 subunits of HIV-1 RT are not
synthesized de novo, but are initially translated as part of a lar-
ger 160 kDa polyprotein termed Gag–Pol. In this regard, p66/
p51 HIV-1 RT heterodimer formation is preceded by HIV-1
PR activation and auto-processing, HIV-1 PR-mediated
Gag–Pol processing and possibly p66/p66 RT dimer formation
[16]. Furthermore, since HIV-1 PR is also an obligate dimer, it
has been speculated that Gag–Pol/Gag–Pol interactions may
drive PR activation [34–36]. Due to its size and propensity to
dimerize, HIV-1 RT may contribute to the formation of
Gag–Pol/Gag–Pol dimers. In light of this, we have investigated
the eﬀect that EFV has on RT homodimer interactions and
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polyprotein.
Using a combination of Y2H assays, in vitro binding assays
and SEC, we demonstrate that EFV can also enhance both RT
p66/p66 and p51/p51 homodimer interactions. Furthermore,
the SEC analyses demonstrated a dramatic shift in equilibrium
to homodimer formation when RT p66 or p51 was incubated
in the presence of a 1-fold molar excess of EFV. These data
suggest that one molecule of drug is suﬃcient to enhance
p66/p66 and p51/p51 homodimerization and that both p66
and p51 in the context of homodimers possess an NNRTI
binding site. In crystal structures of HIV-1 RT, there is only
one NNRTI binding site per heterodimer that is located in
the p66 subunit [2]. The formation of p51/p51 homodimers
in the presence of EFV suggests that in the context of this
homodimer, one of the p51 subunits must adopt a conforma-
tion capable of binding NNRTIs. An alternative explanation
for the observed enhancement of p51/p51 homodimerization
by EFV is that EFV may act as a glue to cross-link two p51
molecules. However, we believe it is more likely that EFV
binds to p51 in a similar manner to how it binds to p66 in
the context of the heterodimer as it possesses the amino acids
that comprise the NNRTI binding site and therefore has the
potential to form this pocket under the right conditions.
To evaluate the eﬀect of EFV on Gag–Pol processing, we
used a model 90 kDa HIV-1 Pol polyprotein that is expressed
as a soluble protein in bacteria. This model Pol polyprotein is
similar to the 114 kDa TFR–PR–RT–IN polyprotein that is
generated by an early cleavage event in Gag–Pol, but IN has
been truncated to facilitate protein solubility [unpublished
observations by NSC]. Our data demonstrate that EFV in-
creases the kinetics of processing of the model Pol polyprotein.
These data suggest that EFV binds to p66 in the context of the
Pol polyprotein and either enhances the activation of the HIV-
1 PR by promoting Pol/Pol protein–protein interactions or al-
ters the conformation of the polyprotein thereby increasing the
accessibility of the Pol cleavage sites to HIV-1 PR. More eﬃ-
cient processing to p51 at the later time points in the presence
of EFV is consistent with the drug promoting p66 homodimer-
ization, an intermediate step that has previously been shown to
be critical to RT heterodimer formation in the model Pol poly-
protein expression system [16]. In contrast, nevirapine and del-
avirdine did not enhance the kinetics of processing of the
model Pol protein. Interestingly, we did not observe signiﬁcant
increases in p66 and p51 homodimerization as measured in the
Y2H assay at concentrations of nevirapine (results not shown),
previously shown to enhance RT heterodimerization [22]. SEC
analysis of the impact of nevirapine (present at a 10-fold molar
excess) on p66 homodimerization conﬁrms these data (results
not shown). Taken together, our data suggest a correlation be-
tween the impact of an NNRTI on p66 homodimerization and
its eﬀect on enhancing the kinetics of processing of the model
Pol protein in bacteria.
If EFV induces similar eﬀects on Gag–Pol processing in
HIV-1 infected cells, we would expect increased levels of active
HIV PR in the cells leading to premature intracellular process-
ing of Gag and Gag–Pol polyproteins and inhibition of assem-
bly and budding of viral particles. This phenotype has been
described where Gag–Pol is overexpressed in cells [35,36] or ex-
pressed with a linked PR dimer [37]. Preliminary experiments
in our laboratory demonstrate decreased viral particle release
from HIV-1 transfected cells treated with non-cytotoxic con-centrations of EFV, but not nevirapine or delaviridine. Studies
are in progress to delineate the exact mechanism of this eﬀect.
These data suggest that NNRTIs, which are potent media-
tors of RT dimerization, may impact on the late stages of
the virus life-cycle such as PR activation, Gag–Pol processing
and viral particle release. The proposed eﬀect of EFV on viral
protein processing may have implications when it is used in
combination with PR inhibitors, which inhibit protein process-
ing. In addition, our data suggest that an NNRTI binding
pocket exists in both p66 and p51 homodimers, providing fur-
ther evidence for the context-dependent conformations of the
RT subunits.
Acknowledgments: G.T. was supported by NHMRC Career Develop-
ment Award 235102 and NHMRC Project Grant 235030. S.P.G. is
an investigator of HHMI. N.S.-C. was supported by NIH R01
GM68406-01A1.References
[1] di Marzo Veronese, F., Copeland, T.D., DeVico, A.L., Rah-
man, R., Oroszlan, S., Gallo, R.C. and Sarngadharan, M.G.
(1986) Characterization of highly immunogenic p66/p51 as the
reverse transcriptase of HTLV-III/LAV. Science 231, 1289–
1291.
[2] Kohlstaedt, L.A., Wang, J., Friedman, J.M., Rice, P.A. and
Steitz, T.A. (1992) Crystal structure at 3.5 A˚ resolution of HIV-1
reverse transcriptase complexed with an inhibitor. Science 256,
1783–1790.
[3] Jacobo-Molina, A., et al. (1993) Crystal structure of human
immunodeﬁciency virus type 1 reverse transcriptase complexed
with double-stranded DNA at 3.0 A˚ resolution shows bent DNA.
Proc. Natl. Acad. Sci. USA 90, 6320–6324.
[4] Hostomsky, Z., Hostomska, Z., Fu, T.B. and Taylor, J. (1992)
Reverse transcriptase of human immunodeﬁciency virus type 1:
functionality of subunits of the heterodimer in DNA synthesis. J.
Virol. 66, 3179–3182.
[5] Wang, J., Smerdon, S.J., Jager, J., Kohlstaedt, L.A., Rice, P.A.,
Friedman, J.M. and Steitz, T.A. (1994) Structural basis of
asymmetry in the human immunodeﬁciency virus type 1 reverse
transcriptase heterodimer. Proc. Natl. Acad. Sci. USA 91, 7242–
7246.
[6] Le Grice, S.F., Naas, T., Wohlgensinger, B. and Schatz, O. (1991)
Subunit-selective mutagenesis indicates minimal polymerase activ-
ity in heterodimer-associated p51 HIV-1 reverse transcriptase.
EMBO J. 10, 3905–3911.
[7] Gorelick, R.J. and Henderson, L.E. (1994) in: Human Retrovi-
ruses and AIDS (Myers, G., Korber, B., Wain-Hobson, S., Jeang,
K.-T., Henderson, L. and Pavalakis, G., Eds.), Analyses III, pp.
2–5, The Los Alamos National Laboratory, Los Alamos, NM.
[8] Vogt, V.M. (1996) Proteolytic processing and particle maturation.
Curr. Top. Microbiol. Immunol. 214, 95–121.
[9] Kaplan, A.H., Manchester, M. and Swanstrom, R. (1994) The
activity of the protease of human immunodeﬁciency virus type 1 is
initiated at the membrane of infected cells before the release of
viral proteins and is required for release to occur with maximum
eﬃciency. J. Virol. 68, 6782–6786.
[10] Lindhofer, H., von der Helm, K. and Nitschko, H. (1995) In vivo
processing of Pr160gag-pol from human immunodeﬁciency virus
type 1 (HIV) in acutely infected, cultured human T-lymphocytes.
Virology 214, 624–627.
[11] Pettit, S.C., Gulnik, S., Everitt, L. and Kaplan, A.H. (2003) The
dimer interfaces of protease and extra-protease domains inﬂuence
the activation of protease and the speciﬁcity of GagPol cleavage.
J. Virol. 77, 366–374.
[12] Louis, J.M., Dyda, F., Nashed, N.T., Kimmel, A.R. and Davies,
D.R. (1998) Hydrophilic peptides derived from the transframe
region of Gag–Pol inhibit the HIV-1 protease. Biochemistry 37,
2105–2110.
[13] Almog, N., Roller, R., Arad, G., Passi-Even, L., Wainberg, M.A.
and Kotler, M. (1996) A p6Pol-protease fusion protein is present
384 G. Tachedjian et al. / FEBS Letters 579 (2005) 379–384in mature particles of human immunodeﬁciency virus type 1. J.
Virol. 70, 7228–7232.
[14] Louis, J.M., McDonald, R.A., Nashed, N.T., Wondrak, E.M.,
Jerina, D.M., Oroszlan, S. and Mora, P.T. (1991) Autoprocessing
of the HIV-1 protease using puriﬁed wild-type and mutated fusion
proteins expressed at high levels in Escherichia coli. Eur. J.
Biochem. 199, 361–369.
[15] Wondrak, E.M., Nashed, N.T., Haber, M.T., Jerina, D.M. and
Louis, J.M. (1996) A transient precursor of the HIV-1 protease.
Isolation, characterization, and kinetics of maturation. J. Biol.
Chem. 271, 4477–4481.
[16] Sluis-Cremer, N., Arion, D., Abram, M.E. and Parniak, M.A.
(2004) Proteolytic processing of an HIV-1 pol polyprotein
precursor: insights into the mechanism of reverse transcriptase
p66/p51 heterodimer formation. Int. J. Biochem. Cell. Biol. 36,
1836–1847.
[17] De Clercq, E. (1998) The role of non-nucleoside reverse trans-
criptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
Antiviral Res. 38, 153–179.
[18] Pedersen, O.S. and Pedersen, E.B. (1999) Non-nucleoside reverse
transcriptase inhibitors: the NNRTI boom. Antiviral Chem.
Chemother. 10, 285–314.
[19] Tachedjian, G. and Goﬀ, S.P. (2003) The eﬀect of NNRTIs on
HIV reverse transcriptase dimerization. Curr. Opin. Invest. Drugs
4, 966–973.
[20] Smerdon, S.J., Jager, J., Wang, J., Kohlstaedt, L.A., Chirino,
A.J., Friedman, J.M., Rice, P.A. and Steitz, T.A. (1994) Structure
of the binding site for nonnucleoside inhibitors of the reverse
transcriptase of human immunodeﬁciency virus type 1. Proc.
Natl. Acad. Sci USA 91, 3911–3915.
[21] Tantillo, C., et al. (1994) Locations of anti-AIDS drug binding
sites and resistance mutations in the three-dimensional structure
of HIV-1 reverse transcriptase. Implications for mechanisms of
drug inhibition and resistance. J. Mol. Biol. 243, 369–387.
[22] Tachedjian, G., Orlova, M., Saraﬁanos, S.G., Arnold, E. and
Goﬀ, S.P. (2001) Nonnucleoside reverse transcriptase inhibitors
are chemical enhancers of dimerization of the HIV type 1 reverse
transcriptase. Proc. Natl. Acad. Sci. USA 98, 7188–7193.
[23] Szilvay, A.M., Nornes, S., Haugan, I.R., Olsen, L., Prasad, V.R.,
Endresen, C., Goﬀ, S.P. and Helland, D.E. (1992) Epitope
mapping of HIV-1 reverse transcriptase with monoclonal anti-
bodies that inhibit polymerase and RNase H activities. J. Acquir.
Immune Deﬁc. Syndr. 5, 647–657.
[24] Nilsen, B.M., Haugan, I.R., Berg, K., Olsen, L., Brown, P.O. and
Helland, D.E. (1996) Monoclonal antibodies against human
immunodeﬁciency virus type 1 integrase: epitope mapping and
diﬀerential eﬀects on integrase activities in vitro. J. Virol. 70,
1580–1587.
[25] Tachedjian, G., Aronson, H.E. and Goﬀ, S.P. (2000) Analysis of
mutations and suppressors aﬀecting interactions between thesubunits of the HIV type 1 reverse transcriptase. Proc. Natl.
Acad. Sci. USA 97, 6334–6349.
[26] Jacques, P.S., Wohrl, B.M., Howard, K.J. and Le Grice, S.F.
(1994) Modulation of HIV-1 reverse transcriptase function in
‘‘selectively deleted’’ p66/p51 heterodimers. J. Biol. Chem. 269,
1388–1393.
[27] Le Grice, S.F. and Gruninger-Leitch, F. (1990) Rapid puriﬁcation
of homodimer and heterodimer HIV-1 reverse transcriptase by
metal chelate aﬃnity chromatography. Eur. J. Biochem. 187, 307–
314.
[28] Rose, M.D., Winston, F. and Hieter, P. (1990) Methods in Yeast
Genetics, a Laboratory Course Manual, Cold Spring Harbor
Laboratory Press, New York.
[29] Tachedjian, G., Aronson, H.E., de los Santos, M., Seehra, J.,
McCoy, J.M. and Goﬀ, S.P. (2003) Role of residues in the
tryptophan repeat motif for HIV-1 reverse transcriptase dimer-
ization. J. Mol. Biol. 326, 381–396.
[30] Le Grice, S.F., Cameron, C.E. and Benkovic, S.J. (1995)
Puriﬁcation and characterization of human immunodeﬁciency
virus type 1 reverse transcriptase. Methods Enzymol. 262, 130–
144.
[31] Restle, T., Muller, B. and Goody, R.S. (1990) Dimerization of
human immunodeﬁciency virus type 1 reverse transcriptase. A
target for chemotherapeutic intervention. J. Biol. Chem. 265,
8986–8988.
[32] Divita, G., Rittinger, K., Restle, T., Immendorfer, U. and Goody,
R.S. (1995) Conformational stability of dimeric HIV-1 and HIV-2
reverse transcriptases. Biochemistry 34, 16337–16346.
[33] Sluis-Cremer, N., Dmitrienko, G.I., Balzarini, J., Camarasa, M.J.
and Parniak, M.A. (2000) Human immunodeﬁciency virus type 1
reverse transcriptase dimer destabilization by 1-[Spiro[400-amino-
200,200-dioxo-100,200-oxathiole-500,3 0-[20,50-bis-O-(tert-butyldimethyl-
silyl)-b-D-ribofuranosyl]]]-3-ethylthymine. Biochemistry 39, 1427–
1433.
[34] Kaplan, A.H. and Swanstrom, R. (1991) Human immunodeﬁ-
ciency virus type 1 Gag proteins are processed in two cellular
compartments. Proc. Natl. Acad. Sci. USA 88, 4528–4532.
[35] Park, J. and Morrow, C.D. (1991) Overexpression of the gag-pol
precursor from human immunodeﬁciency virus type 1 proviral
genomes results in eﬃcient proteolytic processing in the absence
of virion production. J. Virol. 65, 5111–5117.
[36] Karacostas, V., Wolﬀe, E.J., Nagashima, K., Gonda, M.A. and
Moss, B. (1993) Overexpression of the HIV-1 gag-pol polyprotein
results in intracellular activation of HIV-1 protease and inhibition
of assembly and budding of virus-like particles. Virology 193,
661–671.
[37] Krausslich, H.G. (1991) Overexpression of the HIV-1 gag-pol
polyprotein results in intracellular activation of HIV-1 protease
and inhibition of assembly and budding of virus-like particles.
Proc. Natl. Acad. Sci. USA 88, 3213–3217.
